With BlueRock Acquisition, Bayer Plans to Open Trial of Cell Therapy for Parkinson’s

With BlueRock Acquisition, Bayer Plans to Open Trial of Cell Therapy for Parkinson’s
Bayer has announced an agreement to acquire the cell therapy company BlueRock Therapeutics, and plans to open a clinical trial of a potential Parkinson’s stem cell-based treatment this year. BlueRock, which will remain an independent entity under the plan, has a portfolio that focuses on engineered stem cell therapies to treat illnesses in the fields of neurology, cardiology and immunology. Its lead ... read more
Source: Parkinson’s News TodayPublished on 2019-08-19By Jose Marques Lopes, PhD